While estrogen receptor- (ER), progesterone receptor- (PR), and human epidermal growth factor receptor-2- (HER2) positive breast cancers have established therapeutic guidelines2, therapy of triple-negative breast cancer (TNBC) remains challenging without targeted treatment options3–5. Here, ESR1 is linked to triple-negative breast carcinoma.